CRISPR Therapeutics AG (NASDAQ: CRSP) flaunted slowness of -1.14% at $70.16, before settling in for the price of $70.97 at the close. Taking a more long-term approach, CRSP posted a 52-week range of $37.55-$91.10.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The Healthcare Sector giants’ yearly sales growth during the last 5-year period was 33402.13%. Meanwhile, its Annual Earning per share during the time was 10.83%. Nevertheless, stock’s Earnings Per Share (EPS) this year is -199.14%. This publicly-traded company’s shares outstanding now amounts to $80.04 million, simultaneously with a float of $79.80 million. The organization now has a market capitalization sitting at $5.91 billion. At the time of writing, stock’s 50-day Moving Average stood at $73.33, while the 200-day Moving Average is $59.23.
CRISPR Therapeutics AG (CRSP) Ownership Facts and Figures
Sometimes it is also beneficial to study the sentiment of large-scale investors towards the stock of the CRISPR Therapeutics AG industry. CRISPR Therapeutics AG’s current insider ownership accounts for 5.21%, in contrast to 64.27% institutional ownership. According to the most recent insider trade that took place on Mar 15 ’24, this organization’s Chief Executive Officer sold 20,000 shares at the rate of 72.48, making the entire transaction reach 1,449,628 in total value, affecting insider ownership by 208,122. Preceding that transaction, on Mar 15 ’24, Company’s Chief Financial Officer sold 3,524 for 72.69, making the whole transaction’s value amount to 256,160. This particular insider is now the holder of 6,476 in total.
CRISPR Therapeutics AG (CRSP) Earnings and Revenue Records
Going through the last 3-months fiscal report unveiled on the 12/30/2023, it has been observed that the corporation posted $1.1 earnings per share (EPS) during the time that was better the consensus figure (set at -$0.07) by $1.17. Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.52 per share during the current fiscal year.
CRISPR Therapeutics AG’s EPS decrease for this current 12-month fiscal period is -199.14% and is forecasted to reach -4.08 in the upcoming year.
CRISPR Therapeutics AG (NASDAQ: CRSP) Trading Performance Indicators
Let’s observe the current performance indicators for CRISPR Therapeutics AG (CRSP). It’s Quick Ratio in the last reported quarter now stands at 17.54. The Stock has managed to achieve an average true range (ATR) of 3.35. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 15.91.
In the same vein, CRSP’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -1.97, a figure that is expected to reach -1.45 in the next quarter, and analysts are predicting that it will be -4.08 at the market close of one year from today.
Technical Analysis of CRISPR Therapeutics AG (CRSP)
Now, what If we examine the latest scores posted by [CRISPR Therapeutics AG, CRSP]. During the last 5-days, its volume was lower the volume of 1.97 million it reported in year-ago period. During the previous 9 days, stock’s Stochastic %D was recorded 13.43% While, its Average True Range was 3.02.
Raw Stochastic average of CRISPR Therapeutics AG (CRSP) in the period of the previous 100 days is set at 55.50%, which indicates a major rise in contrast to 9.96% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 28.12% that was lower than 67.79% volatility it exhibited in the past 100-days period.
